Revision of PRECAUTIONS

Clarithromycin

March 17, 2026

Therapeutic category

Antibiotic preparations acting mainly on gram-positive bacteria and mycoplasma

Non-proprietary name

Clarithromycin

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

<table>
<tr><th>Current</th><th>Revision</th></tr>
<tr><td>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
Patients receiving pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine mesilate, suvorexant, daridorexant hydrochloride, vornorexant hydrate, lomitapide mesilate, tadalafil (Adcirca), ticagrelor, ibrutinib, ivabradine hydrochloride, venetoclax (relapsed or refractory chronic lymphocytic leukaemia [including small lymphocytic lymphoma] and relapsed or refractory mantle cell lymphoma during the dose escalation phase), lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, voclosporin, or mavacamten

10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)

(N/A)</td><td>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
Patients receiving pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine mesilate, suvorexant, daridorexant hydrochloride, vornorexant hydrate, lomitapide mesilate, tadalafil (Adcirca), ticagrelor, ibrutinib, ivabradine hydrochloride, venetoclax (relapsed or refractory chronic lymphocytic leukaemia [including small lymphocytic lymphoma] and relapsed or refractory mantle cell lymphoma during the dose escalation phase), lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, voclosporin, mavacamten, azelnidipine, or olmesartan medoxomil/azelnidipine

10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
<table>
<tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr>
<tr><td>Azelnidipine
Olmesartan medoxomil/azelnidipine</td><td>The blood concentration of azelnidipine may increase, and its</td><td>The CYP3A inhibitory activity of clarithromycin may suppress</td></tr>
</table>
</td></tr>
</table>

		effects may be enhanced.	the metabolism of these drugs, leading to an increase in their blood concentration.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.